Literature DB >> 6520160

Determination of non-protein-bound N-acetylcysteine in plasma by high-performance liquid chromatography.

B Kågedal, M Källberg, J Mårtensson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6520160     DOI: 10.1016/s0378-4347(00)84705-2

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  8 in total

1.  Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine.

Authors:  B Olsson; M Johansson; J Gabrielsson; P Bolme
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration.

Authors:  J M Burgunder; A Varriale; B H Lauterburg
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  A therapeutic trial with N-acetylcysteine in subjects with hereditary glutathione synthetase deficiency (5-oxoprolinuria).

Authors:  J Mårtensson; J Gustafsson; A Larsson
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

Review 4.  Clinical pharmacokinetics of N-acetylcysteine.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

5.  2-Mercaptopropionate, a novel metabolite formed during treatment with 2-mercaptopropionyl-glycine in cystinuria.

Authors:  J Mårtensson; T Denneberg; B Kågedal
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Pharmacokinetics of N-acetylcysteine in man.

Authors:  L Borgström; B Kågedal; O Paulsen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue.

Authors:  M M Bridgeman; M Marsden; C Selby; D Morrison; W MacNee
Journal:  Thorax       Date:  1994-07       Impact factor: 9.139

8.  Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study.

Authors:  Alberto Papi; Andrea F D Di Stefano; Milko Radicioni
Journal:  Adv Ther       Date:  2020-11-04       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.